- Business Wire•12 hours ago
AstraZeneca today announced that the US Food and Drug Administration has approved a blood-based companion diagnostic for TAGRISSO® . The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor mutation-positive ...
- American City Business Journals•yesterday
Drug developer AstraZeneca PLC will bring more than 350 California employees together in the massive Cove at Oyster Point development in South San Francisco, the company said Tuesday. It comes as Big Pharma players, including Merck & Co. Inc., scout local sites in an effort to cozy up to hot, young Bay Area drug developers . The Cove, now in the second phase of construction by HCP Inc. at Highway 101 and Oyster Point Boulevard, already has landed high-profile biotech startups, such as neurodegenerative drug developer Denali Therapeutics Inc. and cancer drug maker CytomX Therapeutics Inc. But AstraZeneca (AZN) could dwarf those companies with its expected fourth-quarter 2017 move-in.
- Reuters•2 days ago
The $3 billion health initiative set up by Facebook co-founder Mark Zuckerberg and his wife Priscilla Chan has hired one of AstraZeneca's non-executive directors to head up its science drive. The British drugmaker said on Wednesday that Cornelia Bargmann would step down from its board next month to take up a new role as president of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative. Leif Johansson, AstraZeneca's chairman, said the board was sorry to see her leave but understood Bargmann's decision to focus on the new assignment.
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||33.05 x 5300|
|Ask||33.06 x 12000|
|Day's Range||32.77 - 33.47|
|52wk Range||26.97 - 35.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||37.77|
|Avg Vol (3m)||5,981,737|
|Dividend & Yield||0.90 (2.68%)|